Using A549 (p53 wild-type) and H1299 (p53-null) lung cancer cells, we reported that cell treatment with nicotine increased adrenaline and noradrenaline levels, an effect blocked by cell treatment with the α7nAChR inhibitor, α-bungarotoxin (α-BTX), but not by the β-blocker, propranolol [21]. Here, TP53 is linked to lung carcinoma.